AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +75

Market Downturn: 2 Stocks to Buy and Hold Through Any Storm

📉 Markets face volatility due to geopolitical tensions and tariff uncertainty, prompting investors to seek defensive assets.

💊 AbbVie is highlighted as a resilient pharmaceutical stock with a strong portfolio in chronic autoimmune conditions and cancer therapies.

🛡️ Pharma stocks are generally considered defensive because demand for essential medicines remains stable during economic slowdowns.

🔄 AbbVie has a deep product pipeline that helps mitigate risks associated with patent cliff expiration.

👑 The company is a "Dividend King," having increased its dividend payouts for 50 consecutive years, which helps smooth investor losses during downturns.

💻 Microsoft is presented as a defensive tech stock due to its entrenched products like Office used daily by individuals and businesses.

☁️ While Azure is a growth engine, the company maintains consistent revenue from productivity tools even if clients tighten budgets in a recession.

⭐ Microsoft holds an Aaa credit rating, which is higher than that of the U.S. government, signaling rock-solid financial health.

📈 Investors may buy Microsoft at a discount during downturns, expecting it to recover and deliver superior long-term returns as before.

⚠️ AbbVie was notably excluded from The Motley Fool's current list of top 10 stocks recommended by the Stock Advisor team.

🏆 The Stock Advisor report highlights massive historical returns for past picks like Netflix (52x return) and Nvidia (113x return).

📊 The average total return for the Stock Advisor service is reported at 952%, significantly outperforming the S&P 500's 191%.

⏳ All Stock Advisor returns cited are noted as of March 11, 2026.

🧑‍💼 Prosper Junior Bakiny holds no position in the mentioned stocks, while The Motley Fool itself recommends AbbVie and Microsoft.

Bullish Signals
  • AbbVie (NYSE: ABBV) is highlighted as a 'Dividend King' with 50 straight years of payout increases, providing income stability during market downturns.
  • The company possesses a vast pharmaceutical portfolio focused on chronic autoimmune conditions and cancer, sectors which tend to remain resilient even when prescription volumes soften.
  • AbbVie has a deep pipeline that allows it to develop and launch new products, offering a strategic way to navigate the patent cliff.
  • As a defensive stock, AbbVie is positioned to generate consistent revenue and earnings even during severe economic problems or market volatility.
  • The Motley Fool has identified AbbVie as a top stock for investors to prepare for a market downturn, specifically noting its defensive nature against cyclical exposure.
Risk Factors
  • Equity markets have been volatile this year, with some fear the stock market could take a turn for the worse by the end of the year amid geopolitical tensions and lingering tariff-related uncertainty.
  • The article explicitly states that AbbVie was not included in the Motley Fool Stock Advisor's list of 10 best stocks to buy now, potentially implying it is not among their top tier of high-conviction picks.
  • While AbbVie's dividend status as a Dividend King is noted as positive, dividends may not be sufficient to offset losses if the company faces severe challenges or market crashes that impact its payout ability.
  • Microsoft's Azure segment could see growth moderate if clients tighten budgets during a recession, indicating potential downside pressure on its primary growth engine.
  • The article acknowledges that Microsoft is unlikely to emerge entirely unscathed from an economic downturn, with the possibility of falling sharply along with the rest of the market before recovering.
  • Prescription volumes for AbbVie may soften during challenging periods, which could impact consistent revenue generation despite strong demand in specific therapeutic areas.
Full Analysis
The article argues that AbbVie (NYSE: ABBV) is a strong defensive investment suitable for holding during market downturns, citing its resilient business model and deep product pipeline. The text explains that AbbVie's vast portfolio of medicines for chronic autoimmune conditions and cancer maintains consistent revenue even if prescription volumes soften in an economic slowdown. Furthermore, the company utilizes a robust development pipeline to successfully navigate the "patent cliff," ensuring long-term value creation despite losing protection on older blockbuster drugs. A key highlight of the investment case is AbbVie's status as a Dividend King, having increased its payout for over 50 consecutive years. The article emphasizes that this streak indicates management's commitment to maintaining dividends even during challenging times, which can help smooth out losses for investors when equity markets crash. While it warns against speculative biotechs, it positions AbbVie as a high-quality, resilient option distinct from companies with no products or consistent net losses. The piece contextualizes these points by also recommending Microsoft (NASDAQ: MSFT) as a similarly defensive technology stock due to its entrenched software products and strong credit rating. It notes that while Azure growth could moderate in a recession, the company's leadership in cloud computing and AI offers attractive long-term prospects for patient investors who might buy at a discount. The article concludes with an advertisement segment from The Motley Fool Stock Advisor, which claims their 10 best stocks list did not include AbbVie despite their team holding a position in the company. It uses historical examples of Netflix and Nvidia to illustrate the potential returns of following their specific picks, ultimately urging readers to consider joining their community for updated recommendations.